Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guangxi Wuzhou Zhongheng Group Co Ltd
EPS (Diluted)
Guangxi Wuzhou Zhongheng Group Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Guangxi Wuzhou Zhongheng Group Co Ltd
SSE:600252
|
EPS (Diluted)
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
28%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
25%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
¥2
|
CAGR 3-Years
20%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
EPS (Diluted)
¥2
|
CAGR 3-Years
24%
|
CAGR 5-Years
6%
|
CAGR 10-Years
26%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
EPS (Diluted)
¥9
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
N/A
|
|
Guangxi Wuzhou Zhongheng Group Co Ltd
Glance View
Guangxi Wuzhou Zhongheng Group Co Ltd is an intriguing player nestled in China's vibrant industrial landscape. The company, with its roots firmly planted in the southeastern province of Guangxi, has carved a niche for itself in the pharmaceutical and health products sector. Since its establishment, Zhongheng Group has methodically expanded its operations, establishing a robust portfolio that includes everything from the cultivation and processing of Chinese medicinal herbs to the development and manufacturing of pharmaceutical products. This vertical integration ensures quality control from start to finish and allows the company to create an array of products, catering to a diverse market that values traditional Chinese medicine as much as modern health solutions. Zhongheng Group's revenue model hinges on its ability to efficiently blend traditional expertise with modern pharmaceutical practices, capitalizing on the increasing demand for health and wellness products. Through its comprehensive supply chain, the company can produce a competitive range of cost-effective pharmaceuticals and health supplements, positioning itself for profitability in a growing market. Additionally, the company's strategic emphasis on research and development facilitates innovation, allowing for the introduction of new products that meet evolving consumer needs. By maintaining a dynamic array of offerings and leveraging its integrated operations, Guangxi Wuzhou Zhongheng Group Co Ltd continues to navigate the competitive landscape of the pharmaceutical industry, ensuring its place as a key player in China's economic tapestry.
See Also
What is Guangxi Wuzhou Zhongheng Group Co Ltd's EPS (Diluted)?
EPS (Diluted)
-0.1
CNY
Based on the financial report for Dec 31, 2025, Guangxi Wuzhou Zhongheng Group Co Ltd's EPS (Diluted) amounts to -0.1 CNY.
What is Guangxi Wuzhou Zhongheng Group Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
0%
Over the last year, the EPS (Diluted) growth was 0%.